Norditropin Daily denied as not medically necessary by UnitedHealthcare?

UnitedHealthcare requires prior authorization for Norditropin (daily somatropin) under its Commercial growth hormone policy, and defines an "essential" use of growth hormone as therapy to treat a deficiency as part of chronic disease management, distinguishing it from non-essential replacement uses . Covered indications follow FDA labeling and include Congenital Growth Hormone Deficiency (GHD), Pediatric GHD, Transition Phase Adolescent GHD, Adult GHD, and Prader-Willi Syndrome , with additional pediatric indications such as short stature born small for gestational age (SGA) with no catch-up growth by age 2 to 4, and Idiopathic Short Stature (ISS) with height SDS less than -2.25 and growth rates unlikely to permit attainment of adult height in the normal range . Authorization is issued for 12 months at a time , and for transition adolescents the criteria apply during the period from mid to late teens until 6 to 7 years after achievement of adult height . Contraindications per labeling include acute critical illness after open heart or abdominal surgery or multiple accidental trauma, pediatric patients with Prader-Willi syndrome who are severely obese or have upper airway obstruction/sleep apnea, hypersensitivity to somatropin or excipients, and active proliferative or severe non-proliferative diabetic retinopathy . Benefit caps may apply: if the diagnosis is essential the cap is overridden, but if non-essential only the authorization applies and supply limits may be in place . Adult GHD diagnosis typically requires biochemical confirmation (e.g., Insulin Tolerance Test less than 5 ng/mL as the test of choice ) and an endocrinologist must coordinate therapy.

- Submit complete biochemical workup: two failed GH provocative stimulation tests for pediatric GHD per Pediatric Endocrine Society (Grimberg et al., 2016) guidelines, or for adults the Endocrine Society 2011 guideline (Molitch et al.) and AACE/ACE 2019 guideline ( College of endocrinology guidelines for management of growth hormone deficiency in adults and patients transitioning from pediatric to adult care, Endocr Pract 2019;25(11):1191-1232 ) which support diagnosis with documented pituitary/hypothalamic disease plus low IGF-1 - Provide growth charts demonstrating height SDS and growth velocity, citing Pediatric Endocrine Society guidelines providing recommendations for the clinical management of children and adolescents with growth failure ; if transition-age, cite AACE 2019 transition guidance for retesting - Document open epiphyses by X-ray and ongoing growth velocity >2 cm/year, or document clinical reason for slower response (e.g., late puberty), aligned with Pediatric Endocrine Society recommendations - Confirm prescription is written or co-managed by a board-certified endocrinologist with attestation letter - Demonstrate that contraindications do not apply (e.g., negative sleep study and BMI documentation for PWS patients, ophthalmologic clearance for diabetics, no active neoplasm) per Norditropin prescribing information - Argue essential-use designation: GHD as replacement for a chronic pituitary disease meets UHC's own definition of "therapy to treat a deficiency as part of chronic disease management" , which should override benefit caps - For adult continuation, submit IGF-1 normalization, improvement in body composition, lipid profile, and quality-of-life scores (AGHDA) supporting clinical benefit per Endocrine Society guideline ( Molitch ME et al., Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline, J Clin Endocrinol Metab )

## Why UnitedHealthcare Denies Norditropin (Daily Somatropin) for Medical Necessity

UnitedHealthcare frequently denies daily growth hormone therapy (somatropin, brand name Norditropin) on medical-necessity grounds when the submitted documentation does not clearly establish an FDA-recognized indication, demonstrate that diagnostic testing confirms a qualifying deficiency or condition, or show that the prescriber has followed the clinical workup required by UHC's published coverage policy. These denials are routine and highly appealable when the right documentation is assembled.

## Why This Denial Is Appealable

FDA-approved indications for somatropin are well-defined and medically established. If your prescriber determined that your diagnosis falls within a covered indication — such as confirmed growth hormone deficiency, Turner syndrome, Prader-Willi syndrome, small-for-gestational-age without catch-up growth, or adult growth hormone deficiency — and the chart supports that determination, the denial reflects a documentation gap rather than a clinical one. Insurers must apply criteria that are consistent with the FDA label and with the applicable endocrinology society guidelines; a denial that ignores those standards is subject to reversal.

## Federal Appeal Framework

• Internal appeal: You have the right to a full-and-fair internal appeal under ERISA §503 (employer plans) or applicable state law (individual/state-regulated plans). Submit your internal appeal promptly — deadlines typically run from the date of the denial notice.
• External review: Under ACA §2719, after exhausting internal appeal (or after the plan misses its deadline), you may request independent external review. The external-review window is generally four months from the denial date. An accredited Independent Review Organization (IRO) — not UHC — makes the binding decision.
• Expedited review: If your condition is urgent or ongoing treatment will be disrupted, request expedited internal and external review simultaneously. Decisions are required within days rather than weeks.

## Concrete Appeal Steps and Timeline

1. Request the full denial letter and the specific coverage criteria UHC applied (you are entitled to this at no charge). 2. Obtain UHC's published medical policy for growth hormone therapy and read each criterion carefully. 3. Have your prescriber draft a detailed medical-necessity letter (see below). 4. File the written internal appeal, including all supporting documentation, within the plan's stated deadline. 5. If the internal appeal is denied or not decided in time, file for external review immediately.

## Documentation to Gather

• Diagnosis confirmation: Laboratory results confirming the qualifying diagnosis (e.g., stimulation test results for growth hormone deficiency, karyotype for Turner syndrome); imaging or growth-chart records as applicable.
• Clinical severity: Height and weight measurements, growth velocity data, symptom burden, and any quality-of-life or functional assessments in the chart.
• Prior treatment history: Dates and outcomes of any prior interventions or alternative treatments, with objective response data.
• Prescriber medical-necessity letter: A signed letter from your endocrinologist or specialist stating the specific FDA-approved indication, the diagnostic evidence supporting it, why Norditropin is medically necessary, and why alternatives are inadequate or already failed.

## Criteria-Mapping Structure

Print UHC's coverage policy for somatropin. For each listed criterion, create a two-column table:

| UHC Policy Criterion | Supporting Chart Evidence | |---|---| | [Copy criterion verbatim from UHC policy] | [Exact lab value, date, or clinical note from the chart] |

Repeat this for every criterion. Attach the letter, the table, and the underlying records. A point-by-point response demonstrating that each requirement is met is the most effective format for both internal appeal and IRO review.